Department of Hospital Pharmacy, Suqian First Hospital, Suqian 223800, People's Republic of China.
Department of Pharmaceutics, Suqian Clinical College of Xuzhou Medical University, Suqian 223800, People's Republic of China.
Int J Nanomedicine. 2020 May 5;15:3193-3206. doi: 10.2147/IJN.S245289. eCollection 2020.
Certain patients with triple-negative breast cancer cannot tolerate the serious adverse effects of cytotoxic chemotherapy agents, which significantly affect the disease prognosis.
Research into the combined use of photosensitizers and non-cytotoxic antineoplastic drugs for the safe treatment of triple-negative breast cancer is vital.
In this study, the photosensitizer indocyanine green and the natural drug parthenolide were co-loaded into thermosensitive liposomes. Under a near-infrared irradiation, indocyanine green reached excitation levels, releasing heat, and the liposome underwent a phase transition, releasing the drug were researched.
Thus, indocyanine green and parthenolide exert synergistic antineoplastic effects. In the nude mice xenograft MDA-MB-231 tumor model, the tumor inhibition rate of indocyanine green-parthenolide thermosensitive liposomes was approximately 2.08-fold than that of paclitaxel and demonstrated a good initial safety evaluation.
Photosensitizers and non-cytotoxic antineoplastic agents in combination with nanoscale carriers should be further investigated for the treatment of tumors.
某些三阴性乳腺癌患者无法耐受细胞毒性化疗药物的严重不良反应,这对疾病预后有很大影响。
研究将光敏剂和非细胞毒性抗肿瘤药物联合用于安全治疗三阴性乳腺癌非常重要。
本研究将光敏剂吲哚菁绿和天然药物白头翁内酯共同载入热敏脂质体中。在近红外光照射下,吲哚菁绿达到激发水平,释放热量,脂质体发生相变,释放药物。
因此,吲哚菁绿和白头翁内酯发挥协同抗肿瘤作用。在裸鼠 MDA-MB-231 肿瘤移植模型中,吲哚菁绿-白头翁内酯热敏脂质体的肿瘤抑制率约为紫杉醇的 2.08 倍,表现出良好的初步安全性评价。
应进一步研究光敏剂和非细胞毒性抗肿瘤药物与纳米载体的联合应用,以治疗肿瘤。